SCHEMBL2210062

SCHEMBL2210062

COc1cc2nccc(Sc3ccc(Nc4nnc(-c5ccccc5)c5ccccc45)cc3)c2cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.52
PDGFRA P16234 1/20 0.52
FGFR2 P21802 2/20 0.48
MAPT P10636 4/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
EGFR P00533 4/20 0.45
RET P07949 1/20 0.45
LCK P06239 1/20 0.44
POLB P06746 2/20 0.44
ENPP3 O14638 2/20 0.44
PRNP P04156 1/20 0.44
RECQL P46063 1/20 0.44
ATM Q13315 1/20 0.43
RIPK2 O43353 1/20 0.43
EPHB2 P29323 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16233095 0.90 MAP2K1 (0.44) KDRPDGFRAFGFR2MAPTLMNA
SCHEMBL15663572 0.90 MAPT (0.53) KDRPDGFRAMAPTLMNAALDH1A1
SCHEMBL2211159 0.88 MAPT (0.53) KDRPDGFRAMAPTLMNAALDH1A1
SCHEMBL15663720 0.88 MAPT (0.45) KDRMAPTLMNAALDH1A1KDM4E
SCHEMBL15663631 0.87 MAPT (0.43) KDRPDGFRAFGFR2MAPTLMNA
SCHEMBL15663348 0.86 MAPT (0.47) KDRMAPTLMNAALDH1A1KDM4E
SCHEMBL2210377 0.85 ENPP3 (0.50) KDRMAPTLMNAALDH1A1KDM4E
SCHEMBL2209534 0.84 MAPT (0.48) KDRMAPTLMNAALDH1A1KDM4E
SCHEMBL2206693 0.83 ENPP3 (0.47) KDRMAPTALDH1A1KDM4EHPGD
SCHEMBL15663696 0.83 MAPT (0.52) KDRPDGFRAMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US claimed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US claimed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 KDR 644/4885PDGFRA 1102/4885FGFR2 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.